Innovent (1801.HK) earnings: next date, last results and guidance
When is Innovent's next earnings date, and what were its last results?
Last results
- SalesRMB8.62 billion+45 %
Innovent's own figures for the half-year to June 2026. Growth is on a year earlier.
New accounts get one company's ready report free. No card.
Executive summary + 8 chapters · 16,151 words · 162 sources
What has Innovent guided for 2030?
Management still points to RMB20bn of product revenue in 2027. Its newer ambition is RMB35–40bn of total revenue in 2030, alongside at least five molecules in global Phase III development, launches in the United States and Europe, and margins approaching leading pharmaceutical peers.
Has Innovent kept its past promises?
Management has also produced achievements that support its rewards. In March 2025, Innovent identified mazdutide approvals for obesity and diabetes as a cornerstone of expansion beyond cancer. Both approvals followed during 2025, and the company reported its first full year of profit. Those results show execution, but they do not by themselves prove that compensation creates attractive returns on shareholders’ capital.
What is Innovent’s revenue and profit trend?
Revenue growth accelerated to 51.8% in 2024, then eased to 38.4% in 2025. Net income turned to RMB813.565 million in 2025 after losses in every prior year shown; real free cash flow, computed as cash from operations minus capital spending, lease payments, interest paid and stock pay, reached 68.7% of revenue in 2025. Diluted EPS turned positive at RMB0.47 in 2025; stock pay was RMB662.696 million.
What should I watch in Innovent’s next release?
First-half 2026 shows continued commercial growth, but a tax benefit makes the profit increase look stronger than the operating comparison.
IBI343’s next test is whether promising trial news becomes approval and then usable sales.
Questions about Innovent (1801.HK) earnings
Are Innovent's latest earnings out?
Yes. Innovent has reported the half-year to June 2026.
Where could Innovent stock be by 2029?
Our report's forecast is HK$115.62 a share by October 2029, from the HK$89.05 close of October 16, 2026. Innovent stock forecast →
More on Innovent (1801.HK)
Innovent and its rivals
Innovent's own filings
This page gives the results. The report gives the reasons.
The full report: an executive summary and 8 chapters, 16,151 words, 28 tables. Its first page opens here, no account needed.
How it is made: AI reads Innovent's filings, writes the report, checks the numbers against them and cites each source, 162 in this one. How we work · Corrections
Read Innovent's full report freeNew accounts get one company's ready report free. No card.
Information only, not investment advice. The next results date is an expectation until Innovent confirms it. Prices are those of the date shown.